IP Library › Granted Patent US 9,272,280
Granted Patent B2
US 9,272,280 · App. 13/397,398 · Granted Mar 1, 2016

Device, systems and methods for evaluation of hemostasis

Inventors: Francesco Viola (Charlottesville, VA); William F. Walker (Charlottesville, VA); Gregory V. Browne (Victoria, CA); Robert S. Magyar (Victoria, CA); Bjarne Hansen (Victoria, CA); Christopher G. Denny (Victoria, CA)
Assignee: HemoSonics LLC
B01L3/5027B01L3/527B01L2200/04B01L2200/0647B01L2300/027B01L2300/0654B01L2300/0681B01L2300/0867B01L2300/123B01L2300/1805B01L2400/049B01L2400/0436B01L2400/0439B01L2400/0487G01N35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,272,280
App. No.
13/397,398
Granted
Mar 1, 2016
Kind
B2
Abstract

Provided are devices, systems and methods for evaluation of hemostasis. Also provided are sound focusing assemblies.

Claims (5)

1. A device for evaluation of hemostasis, comprising:

a plurality of test chambers each configured to receive blood of a test sample, each test chamber comprising a reagent or combination of reagents, wherein each chamber is configured to be interrogated to determine a hemostatic parameter of the blood received therein;

a first chamber of the plurality comprising a first reagent or a first combination of reagents that interact with the blood received therein, wherein the first reagent, or a reagent included in the first combination of reagents, is an activator of coagulation; and

a second chamber of the plurality comprising a second combination of reagents that interact with blood of the test sample received therein, the combination including an activator of coagulation and one or both of abciximab and cytochalasin D.

2. The device of claim 1 , wherein the first chamber comprises a first combination of reagents including one or more of kaolin, celite, glass, thrombin, ellagic acid, and tissue factor, and wherein the second chamber comprises a second combination of reagents including one or more of kaolin, celite, glass, thrombin, ellagic acid, and tissue factor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2012
From: BROWNE, GREGORY V.; MAGYAR, ROBERT S.; HANSEN, BJARNE; PLATT, EXECUTRIX OF ESTATE OF CHRISTOPHER G. DENNY, KAREN
To: HEMOSONICS LLC
Reel/Frame 028119/0835 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2012
From: VIOLA, FRANCESCO; WALKER, WILLIAM F.
To: HEMOSONICS LLC
Reel/Frame 028119/0920 →
Continuity (2)
Provisional Application 61443088 · Feb 15, 2011
Related Publication 20120329082A1 · Dec 27, 2012